Characteristics of patients at the trial baseline
| Overall | Placebo | 30 g FMT | 60 g FMT | P | |
| All patients | 164 | 55 | 54 | 55 | |
| Age, years | 39.9±9.0 | 41.2±13.7 | 39.2±12.4 | 39.3±13.2 | 0.672 |
| Sex, female/male | 133/32 | 47/8 | 40/14 | 46/9 | 0.189 |
| IBS-D | 63 | 21 | 22 | 20 | |
| IBS-C | 62 | 22 | 20 | 20 | 0.989 |
| IBS-M | 39 | 12 | 13 | 14 | |
| IBS-SSS score | 313.4±80.3 | 315.2±77.1 | 311.8±76.8 | 313.9±87.3 | 0.975 |
| Birmingham IBS-S score | 24.3±7.1 | 23.2±8.1 | 26.5±6.0 | 25.2±6.8 | 0.050 |
| IBS-QoL score | 113.5±21.8 | 117.8±19.7 | 109.1±22.7 | 113.4±22.4 | 0.117 |
| SF-NDI score | 30.2±7.7 | 29.9±1.6 | 29.7±7.1 | 30.9±8.4 | 0.728 |
| FAS score | 31.1±4.9 | 30.6±4.9 | 31.4±5.1 | 31.3±4.8 | 0.634 |
| DI | 2.8±1.1 | 2.7±1.1 | 2.8±1.0 | 2.9±1.0 | 0.781 |
| Patients with dysbiosis | (64) | (67) | (57) | (67) | 0.578 |
| PPI medication | 59 (35.8) | 21 (38.2) | 20 (36.4) | 18 (32.7) | 0.810 |
| Birth-control medication | 84 (50.9) | 25 (45.5) | 29 (52.7) | 30 (54.5) | 0.601 |
| Antimigraine medication | 12 (7.3) | 3 (5.5) | 5 (9.1) | 4 (7.3) | 0.764 |
| Medication against asthma/allergies | 18 (10.9) | 6 (10.9) | 7 (12.7) | 5 (9.1) | 0.829 |
| Medication with levothyroxine | 3 (1.8) | 1 (1.8) | 0 (0) | 2 (3.6) | 0.361 |
| Medication with heart/vascular drugs | 6 (3.6) | 3 (5.5) | 2 (3.6) | 1 (1.8) | 0.595 |
Data are mean±SD, n, n/n, (%) or n (%) values.
DI, dysbiosis index; FAS, Fatigue Assessment Scale; FMT, faecal microbiota transplantation; IBS, irritable bowel syndrome; IBS-QoL, IBS Quality of Life; IBS-SSS, IBS Severity Scoring System; PPI, proton-pump inhibitor; SF-NDI, Short-Form Nepean Dyspepsia Index.